About Edward Hurwitz
Edward Hurwitz is a director and 10% owner at Dyne Therapeutics.
Form D filings name Edward Hurwitz as a director at Recode Therapeutics.
Edward Hurwitz reports to the SEC as a director, officer or major shareholder of 11 public companies, including Macrogenics (MGNX), Applied Genetic Technologies (AGTC) and Turmeric Acquisition (TMPM).
Edward Hurwitz first appears on SEC filings in 2006.
Experience
This experience comes from SEC filings. The years are when the filings name Edward Hurwitz in the role, so the role may have started earlier or lasted longer.
DI
Dyne Therapeutics, Inc.
Director and 10% owner
2020 – 2026 · Public company (DYN)
MI
Macrogenics Inc.
Director
2013 – 2026 · Public company (MGNX)
AC
Applied Genetic Technologies Corp.
Director
2014 – 2022 · Public company (AGTC)
TC
Turmeric Acquisition Corp.
Chief Financial Officer
2020 · Public company (TMPM)
TI
Tvardi Therapeutics, Inc.
Director and 10% owner
2014 · Public company (TVRD)
VI
Viracta Therapeutics, Inc.
Director and 10% owner
2009 – 2013 · Public company (VIRX)
AI
Aegerion Pharmaceuticals, Inc.
10% owner
2010 – 2012 · Public company (AEGR)
MI
Molecular Templates, Inc.
10% owner
2008 – 2009 · Public company (MTEM)
RC
Raptor Pharmaceutical Corp
10% owner
2006 – 2009 · Public company (RPTP)
NI
NeurogesX Inc
10% owner
2007 · Public company (NGSX)
CI
Cotherix Inc.
Reporting person
2007 · Public company (CTRX)
Key Colleagues at Startups
The people Edward Hurwitz works with at each company, as listed on that company's latest Form D.
Recode Therapeutics, Inc. · Form D, Oct 23, 2025
RH
Rana Al-Hallaq
Director
PM
Patricia Millican
Director
SS
Shehnaaz Suliman
Executive officer and director
AC
Alan Colowick
Director
DL
David Lockhart
Executive officer
DM
Dean Mitchell
Director
BZ
Basheer Zada
Director
IP
Inai Park
Director
HK
Helen Kim
Director
PT
Peter Thompson
Director
Rakhshita Dhar
Director